Premium
Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second‐generation tyrosine kinase inhibitors
Author(s) -
Breccia Massimo,
Stagno Fabio,
Gozzini Antonella,
Abruzzese Elisabetta,
Latagliata Roberto,
Rossi Antonella Russo,
Sorà Federica,
Porrini Raffaele,
Vigneri Paolo,
Trawinska Malgorzata,
Montefusco Enrico,
Sica Simona,
Specchia Giorgina,
Santini Valeria,
Alimena Giuliana
Publication year - 2011
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.22020
Subject(s) - myeloid leukemia , medicine , tyrosine kinase , oncology , tyrosine kinase inhibitor , cancer research , cancer , receptor
In this study, we confirm the validity of the proposed Hammersmith score, which identifies three risk categories of patients and establish its strength on a large group of 128 chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors (TKIs) after being resistant to imatinib. Sixty-one patients were identified as good risk group, 27 patients as intermediate risk group, and 40 patients as poor risk group. The 1-year cumulative incidence of complete cytogenetic response was 73% in good risk patients, 40% in intermediate risk patients, and 22% in poor risk patients (P = 0.0001). Event-free survival at 3-year was 89% in good risk group, 70% in intermediate group, and 54% in poor risk group (P = 0.0001); the estimated 3-year progression-free survival was 95% in good risk category, 93% in intermediate risk category, and 87% in poor risk category (P = 0.05). Kaplan–Meier estimated that the 3-year overall survival was 100% in good risk category, 93% in intermediate risk category, and 82% in poor risk category (P = 0.04). In conclusion, some prognostic factors before starting second-generation TKIs might predict cytogenetic response and outcome. The so-called Hammersmith score was not yet validated in large series of patients: we demonstrated that this score is able to discriminate patients at high risk of failure and consequent progression before treatment with second-generation TKIs